Genelux
Genelux Corporation, based in San Diego, CA, is a Phase 3 biopharmaceutical company dedicated to advancing immuno-oncology through innovative therapeutics that address significant unmet medical needs in cancer treatment. Their lead product candidate, Olvi-Vec, utilizes a modified form of the oncolytic vaccinia virus to target and kill tumor cells while sparing normal cells, thereby enhancing the immune response against various cancers.
The company's proprietary CHOICE discovery platform has enabled the development of over 500 unique versions of the vaccinia virus, each engineered for optimal therapeutic efficacy. Genelux is currently recruiting patients for its OnPrime Phase 3 clinical trial in platinum-resistant refractory ovarian cancer, as well as preparing for a Phase 2 trial in recurrent non-small cell lung cancer, demonstrating their commitment to providing innovative solutions for challenging cancer cases.
Generated from the website
Also at this address
You might also like
Partial Data by Foursquare.


